

Press Release
4. Oktober 2006

NeuroBiotec reaches important milestone in development of its anti-Parkinson product Lisuride TDS

After the successful conclusion of its clinical trials the submission of Lisuride TDS to the European Medicines Agency EMEA is scheduled for the beginning of 2007.

In Phase II/III clinical studies NeuroBiotec Pharma AG (NBT Pharma AG) has obtained good evidence of efficacy and safety of its Lisuride patch (*Lisuride TDS*) as combination therapy for Parkinson's disease as first indication. Submission for approval of *Lisuride TDS* in the European Union is being prepared for the beginning of 2007

The clinical development of *Lisuride TDS* for the treatment of Restless Legs Syndromes (RLS) as well as the injectable form of *Lisuride* (*Lisuride sc*) for late-stage is in Phase III with results and subsequent submission expected in 2007.

NeuroBiotec GmbH, Berlin, recently took over all shares of the Swiss company Axxonis Pharma GmbH in Appenzell and was converted into NeuroBiotec Pharma AG which now has more than 20 employees at two locations, Berlin and Appenzell.

On 2 October 2006 the first part of the current financing round was closed with a total of 7 million Euros. This prepares for an initial public offering (IPO) and the further growth and success of the company thus can be secured.

NeuroBiotec GmbH was founded by Dr. Reinhard Horowski and Dr. Johannes Tack in 2001. The company develops new application forms and new drugs for submission to the regulatory authorities.

contact:

Thomas Fröhlich

NeuroBiotec Pharma AG
Tegeler Straße 6
13353 Berlin
Germany

Tel: +49 (0)30 460 619 17
Fax: +49 (0)30 460 619 22

Email:
t.froehlich@neurobiotec.com

Internet:
www.neurobiotec.com